Home  |  Contact

UniProtKB/Swiss-Prot P00966: Variant p.Asp296Gly

Argininosuccinate synthase
Gene: ASS1
Variant information

Variant position:  296
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Aspartate (D) to Glycine (G) at position 296 (D296G, p.Asp296Gly).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (D) to glycine (G)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CTLN1.
Any additional useful information about the variant.



Sequence information

Variant position:  296
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  412
The length of the canonical sequence.

Location on the sequence:   MKSRGIYETPAGTILYHAHL  D IEAFTMDREVRKIKQGLGLK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         MKSRGIYETPAGTILYHAHLDIEAFTMDREVRKIKQGL-GLK

Mouse                         MKSRGIYETPAGTILYHAHLDIEAFTMDREVRKIKQGL-GL

Rat                           MKSRGIYETPAGTILYHAHLDIEAFTMDREVRKIKQGL-GL

Bovine                        MKSRGIYETPAGTILYHAHLDIEAFTMDREVRKIKQGL-GL

Chicken                       MKSRGIYETPAGTILYHAHLDIEAFTMDREVRKIKQGL-SL

Xenopus laevis                MKSRGIYETPAGTILYQAHLDIEAFTMDREMRKIKQQL-SQ

Xenopus tropicalis            MKSRGIYETPAGTILYQAHLDVEAFTMDREVRKIKQHL-SQ

Zebrafish                     MKSRGIYETPGGTVLLQAHLDIETFTMDREVRKIKQSL-GI

Drosophila                    LKSRGVYETPGGTILFAAHQDLEVFALDREVLRTKQVL-RD

Baker's yeast                 LKSRGCYEQAPLTVLRKAHVDLEGLTLDKEVRQLRDSFVTP

Fission yeast                 LKSRGCYETPGLTILRTAHMDLEGLTMEREVRALRDQFVTF

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 412 Argininosuccinate synthase
Binding site 282 – 282 Citrulline
Helix 285 – 301


Literature citations

Mutations and polymorphisms in the human argininosuccinate synthetase (ASS1) gene.
Engel K.; Hoehne W.; Haeberle J.;
Hum. Mutat. 30:300-307(2009)
Cited for: VARIANTS CTLN1 PRO-79; HIS-96; GLN-127; TRP-127; PRO-160; GLN-191; PRO-206; CYS-265; THR-277; ILE-284; SER-291; GLY-296; VAL-324; PHE-341; ARG-347 AND ASP-359;

Mutations in the human argininosuccinate synthetase (ASS1) gene, impact on patients, common changes, and structural considerations.
Diez-Fernandez C.; Ruefenacht V.; Haeberle J.;
Hum. Mutat. 38:471-484(2017)
Cited for: VARIANTS CTLN1 27-GLN--LYS-412 DEL; ILE-64; PRO-79; 97-CYS--LYS-412 DEL; CYS-100; HIS-100; ASP-111; CYS-117; 138-GLN--LYS-412 DEL; SER-157; PRO-160; 163-TYR--LYS-412 DEL; PRO-164; LYS-184; ASP-190; PRO-206; ARG-230; ILE-237; PRO-258; VAL-258; CYS-265; 275-GLY--LYS-412 DEL; THR-277; 279-ARG--LYS-412 DEL; ILE-284; PRO-290; SER-291; GLY-296; ASP-299; VAL-302; GLY-306; CYS-307; 311-GLN--LYS-412 DEL; MET-321; SER-324; VAL-324; HIS-335; PHE-341; 344-ARG--LYS-412 DEL; ARG-347; VAL-356; 357-GLN--LYS-412 DEL; ASP-359; 380-GLN--LYS-412 DEL AND PRO-389;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.